Semax Doses Used in Published Studies: What Researchers Reported

People searching for "Semax nasal spray dosage" are usually looking for a number. This page does not contain one, and the reason is not caution for its own sake: the published Semax literature is overwhelmingly made up of animal experiments, and the amounts used in those experiments were chosen to interrogate a biological mechanism in a rat or mouse model, not to establish a human dose. This page is for educational purposes only and is not medical advice; consult a licensed physician about any health decision.

What the searched question assumes, and what the literature actually contains

The phrase "nasal spray dosage" implies that somewhere in the scientific record there is an established human dosing range that has been tested against placebo across defined durations. That is not what the indexed Semax literature looks like. The studies available in the peer-reviewed record are mechanistic and behavioural animal studies, and their titles themselves describe the design: researchers studied Semax in rats with experimental ischaemic infarction of the cerebral cortex (PMID 17603664), in rats after cerebral ischaemia-reperfusion (PMID 32580520), in female mice after spinal cord injury (PMID 40692165), and in rats with 6-OHDA-induced parkinsonism (PMID 28702721).

Each of those papers specified an administered amount, a route and a treatment length in its own methods section. Those specifications are internal to the experiment. They answer the question "what did the study do to the animals?" — not "what amount would a person use?"

Why this guide describes study designs instead of numbers

Reproducing a list of per-kilogram animal amounts next to the word "dosage" creates a false impression of transferability. Three features of the Semax record make that impression particularly misleading:

• The species differ. The studies were conducted in rats and mice. One spinal cord injury study was explicitly run in female mice (PMID 40692165), which is a deliberate design choice that also limits what can be said about other sexes or species.
• The models differ. An amount that produced a measurable transcriptional change after induced cerebral ischaemia (PMID 19633950) was selected for that injury model. It is not a general-purpose quantity.
• The endpoints differ. Some studies measured gene transcription, some measured behaviour, some measured tissue morphology. An amount tuned to move a gene expression readout is not the same thing as an amount tested for a symptom outcome in people.

Animal dosing is conventionally expressed relative to body weight, and body-weight scaling between rodents and humans is not a simple multiplication. Metabolic rate, mucosal surface area, peptidase activity and clearance all differ. This is the standard reason preclinical amounts are treated as hypothesis-generating rather than prescriptive.

What researchers administered, by research area

Cerebral ischaemia and stroke models

The largest cluster of Semax work sits in rodent brain ischaemia. In one study, researchers reported neuroprotective and antiamnesic effects during experimental ischaemic infarction of the cerebral cortex (PMID 17603664). A separate line of work examined transcription, with the study reporting that Semax and the related fragment Pro-Gly-Pro activated transcription of neurotrophins and their receptor genes after cerebral ischaemia (PMID 19633950). A later transcriptome-level analysis in rats following cerebral ischaemia-reperfusion reported protective properties of the ACTH(4-7)PGP peptide at the level of gene expression (PMID 32580520).

In all three, the administered amount, the interval between injury and administration, and the number of administrations were fixed by the experimental protocol. Those three variables are inseparable in ischaemia research: timing relative to the insult is as much a part of the design as the amount, which is one more reason a single number extracted from such a study carries no standalone meaning.

Stress models and peripheral tissue

Two studies moved outside the brain. One examined the influence of ACTH(4-7)-PGP on the morphofunctional state of hepatocytes under chronic emotional and painful stress (PMID 28577097). Another reported anticoagulation and antiplatelet effects under conditions of acute and chronic immobilisation stress (PMID 21113455).

The second of those is worth pausing on. Researchers reported effects on coagulation and platelet function in a stressed animal model (PMID 21113455) — a finding that belongs to the safety conversation as much as the efficacy conversation, and one that has not been characterised across human dosing ranges. Note also the design difference embedded in the title: acute versus chronic stress were separate conditions, meaning duration of the stressor, not only duration of peptide administration, shaped the result.

Neurodegeneration and movement models

In a 6-OHDA lesion model of parkinsonism, the study reported that Semax and Selank affected the behaviour of the lesioned rats (PMID 28702721). More recently, researchers examined Semax and a derivative for their potential to correct pathological impairments in an animal model of Alzheimer's disease (PMID 41479572). The framing in that second paper — "potential" in an animal model — is the framing the authors themselves chose, and it is a more accurate summary of the evidence stage than anything implying an established treatment.

Learning, memory and neurochemistry

One study reported that Semax prevented learning and memory inhibition caused by heavy metals in an animal paradigm (PMID 27411820). Another reported that the ACTH(4-10) analogue activated dopaminergic and serotoninergic brain systems in rodents (PMID 16362768). A developmental study reported that Semax attenuated behavioural and neurochemical alterations following early-life fluvoxamine exposure in white rats (PMID 33418449), where the exposure window itself was part of the design. A methodological paper applied a functional connectomic approach to studying the effects of Selank and Semax (PMID 32342318), illustrating that part of this field is still developing the tools to describe what the peptides do at a network level.

Mechanism at the receptor level

The most recent mechanistic entry reported that Semax targeted the μ opioid receptor gene Oprm1 to promote deubiquitination and functional recovery after spinal cord injury in female mice (PMID 40692165). Mechanistic studies of this type typically use amounts chosen to make a molecular signal detectable in tissue, which is a different optimisation target from tolerability or symptom benefit.

Route: why "nasal spray" is not automatically the studied route

Search interest centres on intranasal use, but route of administration in preclinical work is a protocol variable chosen by the investigators, and it varies across the literature. Route matters because it determines how much peptide reaches which compartment. A peptide delivered to nasal mucosa, injected systemically, or applied directly in a central model will produce different exposure profiles from the same nominal amount. Comparing numbers across studies that used different routes — or assuming a rodent route maps onto a human spray device — is not a valid conversion. When a specific route and duration matter to a reader's understanding of a finding, the correct step is to read that paper's methods section directly rather than rely on a generalised chart.

Duration: treatment length was tied to the model, not to a schedule

In the stress work, administration length was defined against the acute or chronic stress protocol (PMID 21113455). In the developmental fluvoxamine study, the timing was anchored to an early-life exposure window (PMID 33418449). In ischaemia work, administration was anchored to the time of the induced insult (PMID 32580520). None of these durations was selected as a general regimen length. They were selected so that the intervention window matched the biological event under study.

Adverse Events and Safety Signals: What Studies Report

The verified literature summarised here was not designed as human safety research, and it does not contain human tolerability data. What it does contain are physiological observations that a safety-minded reader should weigh:

• Researchers reported anticoagulation and antiplatelet effects in animals under acute and chronic immobilisation stress (PMID 21113455). Effects on clotting and platelet behaviour are the kind of finding that would require careful human characterisation before any conclusion about safety could be drawn.
• One study examined the morphofunctional state of hepatocytes under chronic emotional and painful stress (PMID 28577097), indicating that peripheral organ effects were considered relevant enough to study.
• Researchers reported activation of dopaminergic and serotoninergic brain systems in rodents (PMID 16362768), and a separate study reported effects in a model involving early-life exposure to a serotonergic drug (PMID 33418449). Monoaminergic activity is a plausible site of interaction with other agents, but the verified record does not characterise such interactions in humans.

Absence of reported adverse events in an animal mechanism paper is not evidence of human safety; those papers were not powered or designed to detect it.

How to read a Semax paper's dosing section yourself

1. Identify the species and sex. The spinal cord injury study specified female mice (PMID 40692165); generalisation beyond that is the reader's assumption, not the study's claim.
2. Identify the model. A 6-OHDA lesion (PMID 28702721) or an induced infarct (PMID 17603664) is a specific pathological state, not a proxy for general health.
3. Identify the endpoint. Gene transcription (PMID 19633950) and behaviour (PMID 27411820) are different orders of evidence.
4. Note the route and the timing relative to the insult. Both are part of the result and cannot be separated from the amount.
5. Ask whether a human trial exists. For the questions most people are searching, within this verified set, it does not.

Regulatory context

Semax is not an approved drug in the United States, and peptide material described as "research use only" is not authorised for human administration. Compounded or research-labelled products are not equivalent to approved medicines, and the animal studies cited on this page do not constitute regulatory evidence of efficacy or safety in people. Nothing here should be read as legal or medical guidance.

The bottom line on dosing questions

The honest answer to "what is the Semax dosage?" is that published studies administered amounts chosen for rodent experiments in defined injury and stress models, and researchers reported outcomes at the level of gene transcription, neurochemistry, tissue morphology and animal behaviour (PMID 32580520, PMID 16362768, PMID 41479572). Those amounts describe the experiments. They do not describe a human regimen, and converting them into one is not something the published record supports.

References

• Semax peptide targets the μ opioid receptor gene Oprm1 to promote deubiquitination and functional recovery after spinal cord injury in female mice (British Journal of Pharmacology, 2025)
• Functional Connectomic Approach to Studying Selank and Semax Effects (Doklady Biological Sciences, 2020)
• Semax, synthetic ACTH(4-10) analogue, attenuates behavioural and neurochemical alterations following early-life fluvoxamine exposure in white rats (Neuropeptides, 2021)
• Influence of ACTG(4-7)-PGP (Semax) on Morphofunctional State of Hepatocytes in Chronic Emotional and Painful Stress (Bulletin of Experimental Biology and Medicine, 2017)
• Semax and Pro-Gly-Pro activate the transcription of neurotrophins and their receptor genes after cerebral ischemia (Cellular and Molecular Neurobiology, 2010)
• Anticoagulation and antiplatelet effects of semax under conditions of acute and chronic immobilization stress (Bulletin of Experimental Biology and Medicine, 2010)
• Neuroprotective and antiamnesic effects of Semax during experimental ischemic infarction of the cerebral cortex (Bulletin of Experimental Biology and Medicine, 2006)
• Peptides semax and selank affect the behavior of rats with 6-OHDA induced PD-like parkinsonism (Doklady Biological Sciences, 2017)
• Novel Insights into the Protective Properties of ACTH((4-7))PGP (Semax) Peptide at the Transcriptome Level Following Cerebral Ischaemia-Reperfusion in Rats (Genes, 2020)
• The Potential of the Peptide Drug Semax and Its Derivative for Correcting Pathological Impairments in the Animal Model of Alzheimer's Disease (Acta Naturae, 2025)
• Semax prevents learning and memory inhibition by heavy metals (Doklady Biological Sciences, 2016)
• Semax, an ACTH(4-10) analogue with nootropic properties, activates dopaminergic and serotoninergic brain systems in rodents (Neurochemical Research, 2005)